Figure 5.

Pharmacologic DNA demethylation recapitulates the DUSP22 signature in ALCL cell lines. (A) Changes in percentage methylation (assessed by RRBS) and gene expression (assessed by RNA sequencing) for genes in the DUSP22 signature in 6 ALCL cell lines treated with decitabine (DAC). (B) Average change in expression for 103 CTA genes detectable in ALCL cell lines treated with DAC. (C) DUSP22-associated genes based on gene expression data from the frozen tissue discovery set were enriched among genes whose expression was induced by decitabine in cell lines (see supplemental Methods for additional details). A negative control gene set comprising genes significantly downregulated in DUSP22-rearranged ALCLs showed no evidence of enrichment (FDR, 0.54).